Marianne Stanford

Assistant Professor; Vice President, Research, IMV, Inc.

marianne stanford2

 

Related information:


Email: mstanford@imv-inc.com
Phone: 902-421-5735 ext 5
Fax: 902-492-0888
Mailing Address: 
IMV Inc. 130 Eileen Stubbs Ave., Suite 19, Dartmouth, Nova Scotia Canada B3B 2C4
 
Research Topics:
  • Immunology
  • Vaccinology
  • Microbiology
  • Cancer Immunotherapy
  • Vaccine Development
  • Infectious Disease

Education

B.Sc., Biology (first class) Memorial University of Newfoundland, 1997
M.Sc., Medicine, Memorial University of Newfoundland, 2000
Ph.D., Microbiology and Immunology, Dalhousie University, 2004
Postdoctoral Fellow, BioTherapeutics Research Group, Robarts Research Institute and Department of Microbiology and Immunology, University of Western Ontario, April 2004-September 2007
Postdoctoral Fellow, Ottawa Hospital Research Institute, Ottawa, Ontario, September 2007- October 2010

Research interests

IMV Inc., formerly Immunovaccine Inc., is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin.

Selected publications

•            Langley JM, MacDonald LD, Weir GM, MacKinnon-Cameron D, Ye L, McNeil S, Schepens B, Saelens X, Stanford MM, Halperin SA. A Respiratory Syncytial Virus vaccine based on the Small Hydrophobic protein ectodomain presented with a novel lipid-based formulation is highly immunogenic and safe in adults: a first-in-humans study. J Infect Dis. 2018 Mar 30. doi: 10.1093/infdis/jiy177.

•            Brewer KD, Weir GM, Dude I, Davis C, Parsons C, Penwell A, Rajagopalan R, Sammatur L, Bowen CV, Stanford MM. Unique depot formed by an oil based vaccine facilitates active antigen uptake and provides effective tumour control. J Biomed Sci. 2018 Jan 27;25(1):7. doi: 10.1186/s12929-018-0413-9.

•            MacDonald LD, MacKay A, Kaliaperumal V, Weir G, Penwell A, Rajagopalan R, Langley JM, Halperin S, Mansour M, Stanford MM. Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform. Hum Vaccin Immunother. 2018 Jan 2;14(1):59-66

•            Weir GM, Hrystenko O, Quinton T, Berinstein NL, Stanford MM, Mansour M. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. Journal for ImmunoTherapy of Cancer 18(4):68 2016

•            Berinstein NL, Karkada M, Oza AM, Odunsi K,Villella JA,Nemunaitis JJ, Morse MA, Pejovic T, Bentley J, Buyse M, Nigam R, Weir GM, MacDonald LD,  Quinton T, Rajagopalan R, Sharp K, Penwell A, Sammatur L, Burzykowski T, Stanford MM, Mansour M. Survivin targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. Oncoimmunology. 2015. 2015 May 7;4(8):e1026529. eCollection 2015 Aug

•            Evgin, L., Vaha-Koskela M., Rintoul, J., LeBoeuf F., Falls, T., Barrett J.W., Bell, J.C. and Stanford, M.M. Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity. Molecular Therapy 2010. May;18(5):896-902.

•            Stanford M.M., Shaban M., Barrett J.W., Werden S.J., Gilbert P., Bondy-Denomy J., MacKenzie L., Graham K.C,  Chambers A.F and McFadden G. Myxoma virus oncolysis of primary and metastatic mouse tumours in vivo. Molecular Therapy. 2008 Jan; 16(1): 52-59.

•            Stanford, M.M., Barrett, J.W, Nazarian S.H, Werden, S., and McFadden G. Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells. Journal of Virology (2007) 81(3): 1251-60

Selected awards and honours

  • Faculty of Medicine Postdoctoral Award of Excellence, University of Ottawa, 2008